These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1184596)

  • 1. Measles, mumps and rubella virus vaccines prepared from virus produced by unit process.
    McAleer WJ; Buynak EB; Weibel RE; Villarejos WM; Scattergood EM; Wasmuth EH; McLean AA; Hilleman MR
    J Biol Stand; 1975; 3(4):381-4. PubMed ID: 1184596
    [No Abstract]   [Full Text] [Related]  

  • 2. A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection.
    Frenkel LM; Nielsen K; Garakian A; Cherry JD
    Arch Pediatr Adolesc Med; 1994 Jan; 148(1):57-60. PubMed ID: 8143011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of measles, mumps and rubella viruses by immuno-colorimetric assay and its application in focus reduction neutralization tests.
    Vaidya SR; Kumbhar NS; Bhide VS
    Microbiol Immunol; 2014 Dec; 58(12):666-74. PubMed ID: 25244651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial.
    Swartz TA; Klingberg W; Klingberg MA
    Infection; 1974; 2(3):115-7. PubMed ID: 4606362
    [No Abstract]   [Full Text] [Related]  

  • 6. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up surveillance for antibody in human subjects following live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1979 Nov; 162(2):328-32. PubMed ID: 515009
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
    Just M; Berger R; Just V
    Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
    Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
    Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children.
    Vesikari T; Ala-Laurila EL; Heikkinen A; Terho A; D'Hondt E; André FE
    Am J Dis Child; 1984 Sep; 138(9):843-7. PubMed ID: 6383020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
    Narayan KM; Moffat MA
    Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
    Feldman S; Andrew M; Norris M; McIntyre B; Iyer R
    Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
    André FE; Peetermans J
    Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined live measles, mumps, rubella vaccine. Immunological response.
    Krugman S; Muriel G; Fontana VJ
    Am J Dis Child; 1971 May; 121(5):380-1. PubMed ID: 5091532
    [No Abstract]   [Full Text] [Related]  

  • 18. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
    Molyneaux PJ; Mok JY; Burns SM; Yap PL
    J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles, mumps, and rubella antibodies in vaccinated Baltimore children.
    King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J
    Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
    Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
    J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.